Energenesis Biomedical Co Ltd
TWSE:6657
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Realty Income Corp
NYSE:O
|
Real Estate
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
US |
![]() |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Intrinsic Value
Energenesis Biomedical Co., Ltd. engages in the development of new drugs. [ Read More ]
The intrinsic value of one Energenesis Biomedical Co Ltd stock under the Base Case scenario is 1.39 TWD. Compared to the current market price of 50.8 TWD, Energenesis Biomedical Co Ltd is Overvalued by 97%.
Valuation Backtest
Energenesis Biomedical Co Ltd
Run backtest to discover the historical profit from buying and selling Energenesis Biomedical Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Energenesis Biomedical Co Ltd
Current Assets | 772.5m |
Cash & Short-Term Investments | 752.9m |
Receivables | 1.6m |
Other Current Assets | 18.1m |
Non-Current Assets | 115m |
PP&E | 79.7m |
Intangibles | 29.5m |
Other Non-Current Assets | 5.9m |
Current Liabilities | 21.4m |
Accounts Payable | 209k |
Accrued Liabilities | 10.2m |
Other Current Liabilities | 11m |
Non-Current Liabilities | 4.4m |
Long-Term Debt | 4.4m |
Earnings Waterfall
Energenesis Biomedical Co Ltd
Revenue
|
9.4m
TWD
|
Cost of Revenue
|
-2.8m
TWD
|
Gross Profit
|
6.7m
TWD
|
Operating Expenses
|
-379.1m
TWD
|
Operating Income
|
-372.5m
TWD
|
Other Expenses
|
9.1m
TWD
|
Net Income
|
-363.4m
TWD
|
Free Cash Flow Analysis
Energenesis Biomedical Co Ltd
TWD | |
Free Cash Flow | TWD |
Profitability Score
Profitability Due Diligence
Energenesis Biomedical Co Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Energenesis Biomedical Co Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Energenesis Biomedical Co Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
Energenesis Biomedical Co Ltd's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Energenesis Biomedical Co Ltd
Shareholder Return
Price
Energenesis Biomedical Co Ltd
Average Annual Return |
N/A
|
Standard Deviation of Annual Returns |
N/A
|
Max Drawdown | -48% |
Market Capitalization | 3.9B TWD |
Shares Outstanding | 76 224 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Energenesis Biomedical Co., Ltd. engages in the development of new drugs. The company is headquartered in Taipei City, Taipei. The company went IPO on 2018-08-08. The firm's main product projects include experimental service analysis and reagent sales. The firm's main new drugs include ENERGI-F703, ENERGI-F701, ENERGI-F711, and ENERGI-F706. The ENERGI-F703 indications are diabetic foot ulcers. The ENERGI-F701 indications are abnormal alopecia. The ENERGI-F711 indications are burns. The ENERGI-F706 indications are cachexia.
Contact
IPO
Employees
Officers
The intrinsic value of one Energenesis Biomedical Co Ltd stock under the Base Case scenario is 1.39 TWD.
Compared to the current market price of 50.8 TWD, Energenesis Biomedical Co Ltd is Overvalued by 97%.